NCT00655655: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 96 | US | everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, vatalanib, CGP-79787, PTK787/ZK 222584, pharmacological study, pharmacological studies, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, DCE-MRI, ultrasound imaging, ultrasonography, ultrasound, ultrasound test | Mayo Clinic, National Cancer Institute (NCI) | Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific | 09/09 | 01/18 | | |
